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Apoptosis has been proposed as a key mechanism responsible for CD4+ T cell depletion
and immune dysfunction during HIV infection. We demonstrated that Q-VD-OPH, a caspase
inhibitor, inhibits spontaneous and activation-induced death of T cells from SIV-infected
rhesus macaques (RMs). When administered during the acute phase of infection, Q-VD-
OPH was associated with (a) reduced levels of T cell death, (b) preservation of CD4+/CD8+
T cell ratio in lymphoid organs and in the gut, (c) maintenance of memory CD4+ T cells, and
(d) increased specific CD4+ T cell response associated with the expression of cytotoxic
molecules. Although therapy was limited to the acute phase of infection, Q-VD-OPH–treated
RMs showed lower levels of both viral load and cell-associated SIV DNA as compared with
control SIV-infected RMs throughout the chronic phase of infection, and prevented the
development of AIDS. Overall, our data demonstrate that Q-VD-OPH injection in SIV-
infected RMs may represent an adjunctive therapeutic agent to control HIV infection and
delaying disease progression to AIDS.
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Introduction
Pathogenic HIV and SIV infections of humans and rhesus 
macaques (RMs), respectively, are associated with progressive 
CD4+ T cell depletion and having a short half-life (1, 2). The reg-
ulation of T lymphocyte numbers that occurs physiologically 
during any normal immune response (i.e., the contraction phase) 
is accomplished by the concerted action of two fundamental 
biological mechanisms, known as activation-induced cell death 
(AICD) and death by neglect or cytokine deprivation. AICD, 
which acts to limit the accumulation of T cells that have re-
sponded to a certain antigen, is dependent on the death receptor 
CD95/Fas and associated with the activation of cysteine prote-
ases (caspases) leading to apoptosis. As antigen levels decrease, 
growth factors and cytokines also become scarce, activating the 
proapoptotic Bcl-2 family member Bim, which engages the mito-
chondrial pathway of apoptosis (3–5). The cooperative interplay 
between these two mechanisms of cell death ensures the elimi-
nation of most effector T cells as the system returns to the steady 
state, while allowing the survival of a small pool of long-living, 
self-sustaining memory T cells.
Studies conducted in both pathogenic and nonpathogenic 
models of SIV infection have demonstrated a direct correlation 
between progression to AIDS and the levels of CD4+ T cell apop-
tosis early after infection (6–17). In the context of HIV/SIV infec-
tions, the increased level of apoptosis can be related to the pres-
ence of heightened levels of immune activation (18–20). CD4+ 
T cells from HIV-infected individuals and SIV-infected RMs are 
highly sensitive to Fas-mediated apoptosis (9, 14, 21–24), which is 
prevented by caspase inhibitors such as Z-VAD-FMK (10, 14, 21, 
25–27). However, Z-VAD-FMK interferes with cell proliferation 
(28, 29), thus limiting its potential for clinical use. Furthermore, 
we and others have also shown that the proapoptotic proteins 
Bim and Bak are upregulated in CD4+ T cells from chronically 
HIV-infected individuals and in SIV-infected RMs compared with 
healthy donors (14, 30). However, spontaneous T cell death was 
prevented only to a limited extent by Z-VAD-FMK but prevented 
by cytokines (9, 14, 21, 31, 32).
In addition to viral replication (33–39), in which lysosome 
destabilization is of crucial importance (40), cell death of CD4+ 
T cells can be mediated by viral particles, often defective, that can 
still bind to — and enter into — CD4+ T cells; viral particles thus 
represent potential candidates for the killing of CD4+ T cells in the 
absence of productive infection (11, 23, 24, 41–50). Therefore, the 
HIV-1 envelope protein induces the activation of caspase-3 and 
caspase-8 (47, 51). Whereas Z-VAD-FMK poorly inhibits sponta-
neous cell death (14), other groups have proposed that quiescent 
CD4+ T cells die by caspase-1–mediated cell death triggered by 
abortive viral infections, which initiate inflammatory reactions 
(52), or even by autophagy (53). Thus, several proteases have been 
proposed to regulate the death of primary CD4+ T cells in the con-
text of HIV/SIV infections, and these could serve as therapeutic 
targets. Until now, very few interventions have been tested in vivo 
to prevent CD4+ T cells death in the context of HIV/SIV infections.
In this study, we found that Q-VD-OPH, a broad caspase 
inhibitor, reduces spontaneous and Fas-mediated apoptosis in 
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tors (1, 10-phenanthroline), and a broad caspase inhibitor (Q-VD-
OPH) were tested ex vivo using T cells isolated from chronically 
SIV-infected RMs. Our results showed that Q-VD-OPH inhibits 
spontaneous cell death of CD4+ T cells isolated from peripheral 
lymph nodes (LNs) (axillary and inguinal) and spleen of SIV- 
infected RMs (axillary, 24.9% ± 3.33% versus 15.4% ± 4.59%, P = 
0.019; inguinal, 21.7% ± 5.6% versus 13.5% ± 4.52%, P = 0.006; 
spleen, 33.1% ± 4.9% versus 20.2% ± 3.92%, P = 0.012, for control 
and Q-VD-OPH–treated cells, respectively) (Figure 1A). The effect 
was not restricted to CD4+ T cells, since death of CD8+ T cells of 
SIV-infected RMs was similarly inhibited (axillary, 41% ± 6% ver-
sus 20.7% ± 1.6%, P = 0.017; inguinal, 39.9% ± 3.9% versus 23.1% 
± 2.9%, P = 0.007; spleen, 44% ± 4.4% versus 23.1% ± 2.27%, P 
= 0.0009, for control and Q-VD-OPH–treated cells, respective-
ly), and reached the levels observed for CD8+ T cells isolated from 
healthy RMs (Figure 1B). The other compounds tested had no pre-
ventive effect (data not shown).
Because we have previously observed that Z-VAD-FMK was 
only partly effective in blocking spontaneous T cell death (14), in 
a cell-free system, using recombinant effector caspases as targets, 
we compared the two inhibitors. We demonstrated that Q-VD-
OPH was more effective than Z-VAD-FMK in blocking caspase-3– 
and caspase-7–mediated poly(ADP-ribose) polymerase (PARP) 
cells recovered from the lymphoid organs of SIVmac251-infected 
RMs. Furthermore, we demonstrated that in vivo administration of 
Q-VD-OPH during the acute phase of SIV infection reduced the lev-
els of memory CD4+ T cell apoptosis, while maintaining the CD4+/
CD8+ T cell ratio and preserving the pool of memory CD4+ T cells, 
leading to activation of specific effector CD4+ T cells and expression 
of cytotoxic molecules. Most importantly, Q-VD-OPH–treated RMs 
exhibited reduced viral load and delayed progression to AIDS.
Results
Q-VD-OPH inhibits in vitro spontaneous and activation-mediated 
T cell death. Several proteases (including cysteines, serine, and 
calpain proteases) have been proposed as regulating the death of 
primary CD4+ T cells in the context of HIV/SIV infections. Given 
the lower impact of Z-VAD-FMK on spontaneous cell death, we 
assessed the effectiveness of different compounds in prevent-
ing cell death either spontaneously or after incubation with Fas 
ligand (FasL). Several synthetic protease inhibitors, including an 
inhibitor of autophagy (3-MA), cathepsin inhibitors (Z-FG-NHO-
BzME), calpain inhibitors (ALLN, Z-FA-CHO, calpeptin, and cal-
pastatin), serine protease inhibitors (AEBSF, aprotinin, Elastinal, 
and TLCK), cysteine protease inhibitors (E-64 and leupeptin), 
aspartic protease inhibitor (pepstatin A), metalloprotease inhibi-
Figure 1. Q-VD-OPH prevents ex vivo cell death and enhances proliferation of T cells from SIV-infected RMs. Percentage of dying (A) CD3+CD4+ and 
(B) CD3+CD8+ T cells from axillary (squares) and inguinal (triangles) LNs and from the spleen (circles) of either healthy RMs (RMSIV, –; n = 2) or chronically 
SIV-infected RMs (RMSIV, +; n = 5) in the absence (–, filled symbols) or presence of Q-VD-OPH (Q-VD) (+, open symbols). Animals were sacrificed 6 months 
after infection. Statistical significance was assessed using Wilcoxon’s matched-pairs signed rank test (1-tailed P < 0.05). (C) Percentage of dying CD3+CD4+ 
and CD3+CD8+ T subsets (naive [N], CD45RA+CD62L+; Tcm [CM], CD45RA–CD62L+; Tem [EM], CD45RA–CD62L–; terminally differentiated T [TDT] cells, 
CD45RA+CD62L–) from peripheral blood of SIV-infected RMs (n = 6) in the absence (–) or presence (+) of Q-VD-OPH. (D) Representative flow cytometric 
analysis of phosphatidylserine residue exposure (annexin V staining) on CD3+CD4+ and CD3+CD8+ T cells from peripheral blood of a chronically SIV-infected 
RM incubated overnight in the presence of FasL. (E) Histogram of CD3+CD4+0 and CD3+CD8+ T cells from either healthy (gray boxes, n = 6) or SIV-infected 
RMs (white boxes, n = 8) incubated with FasL in the absence (–) or presence (+) of Q-VD-OPH. (F) PBMCs from SIV-infected RMs (n = 6) were stimulated 
with ConA in the absence or presence of Q-VD-OPH. AICD was assessed after overnight culture by flow cytometry using annexin V. Histogram represents 
the preventive effect calculated as 100 x ((cells untreated – cells+Q-VD)/cells untreated). Statistical significance was assessed using paired Student’s t 
test. Prism was used to present the results in box-and-whisker plots showing the minimum and maximum of all the data. P < 0.05.
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We then decided to analyze in detail the effect of Q-VD-OPH 
on T cell subsets. Immunophenotypical analysis conducted in 
fresh cells recovered from chronically SIV-infected RMs revealed 
that the preventive effect of Q-VD-OPH occurred mainly within 
the effector memory CD4+ T cell population (Tem, CD45RA–
CD62L–) (26.1% ± 3.6 % and 9.5% ± 2.2% for control and Q-VD-
OPH–treated cells, respectively) and to a lesser extent within 
cleavage, which is a prototypical substrate of effector caspases 
(Supplemental Figure 1A; supplemental material available online 
with this article; https://doi.org/10.1172/JCI95127DS1). Further-
more, Q-VD-OPH could also inhibit caspase-1 activity more effi-
ciently than Z-VAD-FMK (Supplemental Figure 1B). These results 
demonstrated the superior efficacy of Q-VD-OPH in blocking 
caspase activation as compared with Z-VAD-FMK.
Figure 2. Q-VD-OPH treatment reduces T cell death in SIV-infected RMs. Percentages of dying CD3+CD4+ and CD3+CD8+ T cells from peripheral LNs (A–D) 
and blood (E–H) of either untreated (placebo, n = 12) or Q-VD-OPH–treated RMs (n = 6) at different times after infection (A, B, E, and F). After overnight 
culture, spontaneous and (C, D, G, and H) FasL-mediated T cell death was measured by flow cytometry using FITC–annexin V. Statistical differences were 
assessed using the Mann–Whitney U test (*0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 0.001). Prism was used to present the results in box-and-whisker 
plots showing the minimum and maximum of all the data.
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dose (Supplemental Figure 3, A and B). Moreover, we analyzed the 
levels of urea, transaminase (alanine aminotransferase [ALAT] and 
aspartate aminotransferase [ASAT]), and creatinine to assess liver 
and renal toxicity. No significant differences were found in any 
of the toxicity parameters evaluated between the sera of animals 
administered 20 mg/kg Q-VD-OPH and those receiving vehicle 
alone (Supplemental Figure 3C). Among the animals treated with 
40 mg/kg only 1 RM (no. 9052) showed higher levels of urea, 
ALAT, and creatinine compared with the placebo-treated (DMSO) 
RMs (Supplemental Figure 3C). Thus, we selected the dose of 20 
mg/kg for the in vivo experiments included in this study.
Six RMs of Chinese origin were treated during the acute phase 
of SIVmac251 infection by intravenous injection of Q-VD-OPH (20 
mg/kg), whereas vehicle was injected in the second group of RMs 
as a control (Supplemental Figure 4). The dosing regimen consisted 
of 5 Q-VD-OPH injections on days 5, 7, 9, 11, and 14 after infection, 
thus covering the peak of T cell apoptosis observed during acute SIV 
infection (13–17). No statistically significant difference was observed 
in red blood cell and platelet counts or hemoglobin concentration 
between treated and untreated RMs, ruling out possible side effects 
of Q-VD-OPH injection during infection (Supplemental Figure 5). 
To monitor the in vivo levels of T cell death, we collected peripheral 
axillary and inguinal LNs from SIV-infected RMs on days 7, 11, 14, 
terminally differentiated CD4+ T cells (CD45RA+CD62L–, 9.5% ± 
2.2% and 4.5% ± 1.5%) (Figure 1C). In addition, Q-VD-OPH pro-
tected CD4+ and CD8+ T cells from (a) FasL-mediated cell death 
(Figure 1, D and E) and (b) AICD, which depends on the Fas/FasL 
pathway (Figure 1F). None of the other inhibitors that we tested 
afforded similar protection (data not shown). As a consequence 
of its antiapoptotic effect, the presence of Q-VD-OPH was asso-
ciated with an increased proportion of proliferating T cells (CFSE 
dilution assay) after stimulation with concanavalin A (ConA) (Sup-
plemental Figure 2).
Overall, these results demonstrated that Q-VD-OPH prevents 
ex vivo spontaneous and Fas-mediated T cell death and enhances 
proliferation of cells isolated from chronically SIV-infected RMs.
In vivo administration of Q-VD-OPH prevents T cell death in 
SIV-infected RMs. To investigate the effect of Q-VD-OPH in vivo, 
we initially performed pharmacokinetic studies in uninfected ani-
mals. Q-VD-OPH was administered at 20 and 40 mg/kg. These 
doses were chosen based on in vivo experiments performed in 
murine models (54, 55). The concentration of Q-VD-OPH was 
measured in the sera sampled at different time points after injec-
tion and in LNs recovered upon 4 hours of treatment. As expected, 
we found the higher concentrations of the compound, both in sera 
and LNs, and highest half-life in animals treated with the higher 
Figure 3. Q-VD-OPH preserves 
T cell homeostasis. CD4+ T cell 
counts of peripheral blood of 
either (A) untreated (placebo,  
n = 12) or (B) Q-VD-OPH– 
treated RMs (n = 6) at different 
times after infection. (C and 
D) CD4+/CD8+ T cell ratio was 
calculated from (C) peripheral 
blood and (D) peripheral LNs 
(axillary and inguinal LNs). 
(E) CD4+/CD8+ T cell ratio was 
calculated from spleen, axillary 
(Ax), inguinal (Ing), and mes-
enteric (Mes) LNs of healthy 
(Naive), of untreated (Placebo), 
and Q-VD-OPH–treated 
SIV-infected (Q-VD, white 
boxes) RMs. Statistical dif-
ferences were assessed using 
the Mann-Whitney U test 
comparing the 2 groups at each 
time point (*P < 0.05; **P < 
0.01; ***P < 0.001). Prism was 
used to present the results in 
box-and-whisker plots showing 
the minimum and maximum 
of all the data.
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to increase during HIV (25, 60) and SIV infections (14, 61). When 
performing analysis on LN-derived CD8+ T cells, we found that, 
as in CD4+ T cells, the levels of spontaneous and FasL-mediated 
apoptosis were lower in Q-VD-OPH–treated SIV-infected RMs as 
compared with control animals during the acute phase of infection 
(Figure 2, B and D). However, in contrast to what we observed for 
LN-derived CD4+ T cells, the effect of Q-VD-OPH on the sponta-
neous and FasL-mediated apoptosis of LN-derived CD8+ T cells 
was limited to the period of treatment, while the preventive antia-
poptotic effect on blood-derived CD8+ T cells was smaller than that 
observed for CD4+ T cells (Figure 2, F and H).
As the level of IL-18, which is a potent inducer of FasL (62, 63), 
is reduced in Q-VD-OPH–treated RMs, we quantified FasL in the 
sera. We found that levels of FasL were reduced in Q-VD-OPH–
treated SIV-infected RMs as compared with control SIV-infected 
animals and that this effect lasted after the cessation of treatment 
(Supplemental Figure 7B).
Together, these results demonstrated that treatment with 
Q-VD-OPH reduced the levels of CD4+ T cell death during the 
acute phase but also after treatment interruption.
Q-VD-OPH treatment prevents CD4+ T cell depletion. We 
then monitored CD4+ T cell depletion in treated compared with 
untreated RMs. The in vivo Q-VD-OPH treatment resulted in a 
higher CD4+ T cell count and higher CD4/CD8 ratios in peripheral 
blood throughout infection (Figure 3, A–C) and higher CD4/CD8 
ratio in LNs (Figure 3D) as compared with control animals. On 
the sacrifice day, we found that the CD4/CD8 ratio in spleen and 
axillary, inguinal, and mesenteric LNs were also higher in Q-VD-
OPH–treated SIV-infected RMs compared with the placebo group 
(Figure 3E) despite a longer duration of SIV. Since high expres-
sion of β7 on CD4+ T cells in peripheral blood is a useful surrogate 
for estimating intestinal CD4+ T cell loss (64), we also assessed 
during the acute phase the dynamics of CD4+ T cells coexpressing 
and 60 after infection. Indeed, the levels of apoptosis in peripheral 
LNs of RM are predictive of progression to AIDS (13, 15, 16). We first 
quantified the number of dying cells in vivo in LNs using a TUNEL 
assay as previously described (13, 16). We observed that the levels 
of TUNEL+ cells were significantly lower in SIV-infected RMs treat-
ed with Q-VD-OPH as compared with untreated animals (Supple-
mental Figure 6, A and B). We then measured, in the sera of treated 
and control RMs, the levels of IL-18, a proinflammatory cytokine 
belonging to the IL-1 superfamily whose maturation is dependent 
on caspase activation (56, 57) and that was previously reported to be 
increased during the acute phase of SIV infection in RMs (58, 59). 
We found that in Q-VD-OPH–treated RMs, IL-18 levels were sig-
nificantly decreased on postinfection (p.i.) days 11 and 14 compared 
with those in control SIV-infected RMs (Supplemental Figure 7A), 
thus suggesting in vivo inhibition of caspase activation.
We then quantified ex vivo the levels of spontaneous and 
FasL-mediated apoptosis of CD4+ T cells isolated from LNs. Our 
data demonstrated lower levels of CD4+ T cell death from LNs iso-
lated from RMs treated with Q-VD-OPH compared with untreated 
RMs. This protective effect was observed on days 7, 11, and 14 after 
infection (Figure 2, A and C). Of note, however, the level of CD4+ T 
cell death remained significantly lower in Q-VD-OPH–treated RMs 
as compared with controls on day 60 after infection, i.e., more than 
6 weeks after the interruption of treatment. This long-term effect 
of Q-VD-OPH administration was confirmed by the observation of 
lower levels of CD4+ T cell death in the peripheral blood up to 1 year 
after treatment (Figure 2, E and G). Furthermore, we also observed 
that the formation of the cleaved form of the effector caspase-3, 
as measured by Western blotting, was prevented in CD4+ T cells 
isolated from Q-VD-OPH–treated RMs as compared with control 
animals (Supplemental Figure 8). This difference was not related 
to a difference in CD95 expression in CD4+ T cells (Supplemen-
tal Figure 9). FasL, the counterpart of CD95, has been reported 
Figure 4. Q-VD-OPH prevents the depletion 
of β7hi CD4+ T cells in SIV-infected RMs. (A) 
Representative flow cytometric analyses of 
coexpression of CD45RA and β7hi integrin 
expression on CD3+CD4+ T cells from peripheral 
blood of healthy RMs (day 0) and of either 
untreated (placebo) or Q-VD-OPH–treated RMs 
(Q-VD) on day 14. (B) Percentages of CD3+C-
D4+CD45RA–β7hi T cell subset of placebo-  
(n = 8) and Q-VD-OPH–treated RMs (n = 6) at 
different time point after infection. (C) sCD14 
was measured in the sera by ELISA at different 
time points p.i. Statistical differences were 
assessed using the Mann-Whitney U test 
(*0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 
0.001). Prism was used to present the results 
in box-and-whisker plots showing the mini-
mum and maximum of all the data.
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CD45RA and β7hi. Our results showed the early loss of the circulat-
ing β7hi CD4+ T cell population in SIV-infected RMs. In contrast, 
such loss was not observed in Q-VD-OPH–treated RMs (Figure 4, 
A and B). Furthermore, we measured the levels of soluble CD14 
(sCD14), which is a well-established marker of microbial translo-
cation associated with the depletion of CD4+ T cells in the intes-
tine and with clinical end points (65–69). We found that sCD14 
was significantly decreased in Q-VD-OPH–treated SIV-infected 
RMs as compared with control animals (Figure 4C).
Because CD4+/CD8+ T cell ratio is considered a strong marker 
of disease progression to AIDS (70), our results demonstrated that 
treatment with Q-VD-OPH afforded long-term protection pre-
serving CD4+ T cell homeostasis.
Q-VD-OPH treatment prevents the loss of memory T cells and 
decreases immune activation. To better understand the repop-
ulation of CD4+ T cells, and because the progressive loss of 
central and effector memory CD4+ T cells is associated with 
AIDS pathogenesis (13, 15, 71–76), we next investigated, in our 
cohort of SIV-infected RMs, the effect of Q-VD-OPH on the 
dynamics of CD4+ T cell subsets. We found that CD4+ Tem 
(CD45RA–CD62L–) cells from LNs of Q-VD-OPH–treated 
SIV-infected RMs were less prone to die as compared with 
LN-derived CD4+ Tem cells of nontreated SIV-infected RMs 
during the acute phase of infection and up to 60 days after 
termination of the treatment (Figure 5A). A similar pattern of 
reduced spontaneous cell death, although to a lesser extent, 
was observed in both central memory (Tcm, CD45RA–CD62L+) 
and terminally differentiated (CD45RA+CD62L–) CD4+ T cells 
(Figure 5A). Although the death of naive CD4+ T cells was low, 
we observed a slight increase in naive CD4+ T cells from LNs of 
Q-VD-OPH–treated SIV-infected RMs. Consistent with this pro-
tective effect of Q-VD-OPH, the percentage of Tem cells among 
the total LN T cell pool was greater in treated SIV-infected RMs 
as compared with control animals (Figure 5A). Of note, CD4+ 
Tcm cells, which are also progressively depleted during patho-
genic SIV infection, were similarly preserved in Q-VD-OPH–
treated RMs as compared with controls (Figure 6A). The distri-
bution of the different T cell subsets among the pool of CD4+ T 
cells (Figure 6C) illustrates the selective preservation of specific 
CD4+ Tcm cell subsets in Q-VD-OPH–treated RMs.
Furthermore, Q-VD-OPH treatment was associated with 
a transient decrease in CD8+ Tem and Tcm cell death in LNs of 
SIV-infected RMs (Figure 5B) and a slight increase in levels of 
naive CD8+ T cells on day 11. As a consequence, Q-VD-OPH–
treated RMs showed a higher percentage of LN-based CD8+ 
Tcm cells as compared with control animals, which exhibited, as 
expected, higher percentages of LN-based CD8+ Tem and termi-
nally differentiated T cells (Figure 5B). As shown in Figure 6, B 
and D, the distribution kinetics of the distinct CD8+ T cell sub-
sets clearly illustrates the differences in the balance of terminally 
differentiated T cells and Tcm cells in Q-VD-OPH–treated and 
untreated RMs. We then assessed the levels of immune activa-
tion of LN CD8+ T cells and found that Q-VD-OPH treatment 
was associated with decreased levels of CD8+ T cell activation, as 
measured by the frequency of CD8+ T cells expressing the acti-
vation markers HLA-DR and Ki-67, as compared with untreated 
controls (Supplemental Figure 10).
Together, these results suggest that Q-VD-OPH treat-
ment improved the overall homeostasis of memory T cells and 
reduced the level of immune activation during the chronic 
phase of SIV infection.
Q-VD-OPH treatment induces SIV-specific CD4+ T effector cells. 
To investigate the impact of Q-VD-OPH on SIV-specific CD4+ T 
cell immune response, we next evaluated the expression of IFN-γ 
and TNF-α by intracellular cytokine staining (ICS) after in vitro 
HIV-2 antigen stimulation (Supplemental Figure 10). The use of 
such crude antigen preparation, as opposed to individual peptides, 
has been validated in our laboratory as well as others as a tool to 
best detect SIV-specific CD4+ T cell responses in the setting of the 
broad MHC genetic polymorphisms present in RMs (13, 77, 78). 
We found that at 2 weeks after infection, the percentage of SIV- 
specific CD4+ T cells expressing IFN-γ and TNF-α was approx-
Figure 5. Q-VD-OPH treatment reduces memory T cell death in SIV-infected 
RMs. Dying CD4+ (A) and CD8+ (B) T cell subsets (naive, CD45RA+CD62L+; 
Tcm, CD45RA–CD62L+; Tem, CD45RA–CD62L–; TDT, CD45RA+CD62L–) of 
either untreated (placebo, n = 12) or Q-VD-OPH–treated RMs (Q-VD, n = 6) 
were quantified after overnight culture by flow cytometry using annexin V 
(spontaneous T cell death). Statistical differences were assessed using the 
Mann-Whitney U test (*0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 0.001). 
Prism was used to present the results in box-and-whisker plots showing the 
minimum and maximum of all the data.
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imately 10-fold higher in Q-VD-OPH–treated than 
control RMs (Supplemental Figure 11A). In vitro T cell 
proliferation, as measured by thymidine incorpora-
tion after 5 days of culture, confirmed the increased 
ability of CD4+ T cells from Q-VD-OPH–treated SIV- 
infected RMs to respond to HIV-2 antigens as compared 
with those isolated from control animals (Supplemental 
Figure 11B).
To determine the effect of Q-VD-OPH on the 
expression of cytotoxic molecules, we next analyzed 
the expression of perforin, granzyme B, and granulysin 
in purified T cells by Western blotting (Supplemental 
Figure 12). Purified CD8+ T cells from untreated SIV- 
infected RMs showed reduced expression of perforin 
and granulysin molecules as compared with those from 
healthy animals, with no full restoration in Q-VD-OPH–
treated SIV-infected RMs (Supplemental Figure 12A). In 
1 SIV-infected RM (lane 4), a higher level of granzyme 
B was found to be associated with the lowest level of 
perforin, which is essential for granzyme B–mediated 
killing. A growing body of evidence suggests that CD4+ 
T cells also can themselves display potent antiviral activ-
ity by killing virus-infected cells including cytomegalo-
virus (79), influenza (80), Friend virus (81), Epstein-Barr 
virus (82), murine poxvirus (83), and BK polyomavirus 
(84). In HIV-infected individuals, the presence of cyto-
lytic HIV-specific CD4+ T cells has been associated 
with control of virus replication and delayed disease 
progression (85–89). Interestingly we observed that 
the expression of perforin, granzyme B, and granulysin 
in CD4+ T cells was preserved or even augmented in 
chronically Q-VD-OPH–treated SIV-infected RMs 
compared with untreated SIV-infected RMs (Supple-
mental Figure 12B). We then assessed the proportion of 
cytotoxic CD4+ T cells by analyzing the expression of 
perforin, granzyme B, and granulysin by flow cytom-
etry. Our results demonstrated that CD4+ T cells from 
Q-VD-OPH–treated SIV-infected RMs expressed 
higher levels of perforin, granzyme B, and granulysin 
than those from naive RMs (Figure 7, A and B). Similarly, 
the frequency and the numbers of CD4+ T cells express-
ing TIA1, the cytotoxic granule-associated protein, 
are preserved under treatment compared with control 
animals in chronically Q-VD-OPH–treated SIV-infected 
RMs (Figure 7, C and D).
Together, these findings indicated that treatment 
with Q-VD-OPH resulted in more robust SIV-specific 
CD4+ T cell responses, associated with higher levels of 
total cytotoxic CD4+ T cells.
Q-VD-OPH reduces viral replication and delays pro-
gression to AIDS. The observations that Q-VD-OPH 
treatment of SIV-infected RMs improves the overall 
homeostasis of CD4+ T cells prompted us to investigate 
the impact of Q-VD-OPH treatment on the levels of SIV 
replication. We found that the levels of viral replication 
were significantly lower in SIV-infected Q-VD-OPH–
treated RMs as compared with control animals (Figure 
Figure 6. Q-VD-OPH inhibits in vivo the depletion of memory T cells in SIV-infected RMs. 
Percentages of (A) CD3+CD4+ and (B) CD3+CD8+ T cell subsets (naive, CD45RA+CD62L+; Tcm, 
CD45RA–CD62L+; Tem, CD45RA–CD62L–; TDT, CD45RA+CD62L–) among total T cells from 
peripheral LNs of either untreated (placebo, n = 12) or Q-VD-OPH–treated RMs (Q-VD, n = 6) at 
different time points after infection. T cell subsets were analyzed by flow cytometry. The pie 
charts represent the distribution of cell subsets among either (C) CD3+CD4+ or (D) CD3+CD8+ T 
cell populations. Statistical differences were assessed using the Mann-Whitney U test (*0.01 
< P < 0.05; **0.001 < P < 0.01; ***P < 0.001). Prism was used to present the results in box-
and-whisker plots showing the minimum and maximum of all the data.
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Together, these results demonstrate that treatment with 
Q-VD-OPH during the acute phase of SIV infection in RMs 
resulted in long-term control of viral replication and delayed 
disease progression.
Discussion
In this study, we have shown that Q-VD-OPH may represent a 
novel compound to be explored as a potential treatment for HIV/
SIV infection due to its strong anti-caspase effect in vitro and 
in vivo, which results in better immunological, virological, and 
clinical outcomes of SIV infection in RMs. We wish to point out 
that while many studies in vivo and in vitro have revealed a clear 
association between HIV/SIV disease progression and the levels 
of T cell death, the current study is the first to our knowledge 
showing, in a highly relevant animal model, that a pharmacolog-
ical inhibitor of caspase has a significant impact on the pathoge-
nicity of an AIDS virus infection.
8A), with an AUC of viral load that was significantly lower during 
the acute phase of SIV infection (i.e., week 1 until week 4, AUC, P = 
0.01) (Figure 5B). Interestingly, viral load continued to decline and 
remained low throughout the chronic phase of infection (Figure 8, 
A and B) despite the short course of treatment (the last Q-VD-OPH 
injection was administrated on day 14 p.i.). We next measured the 
levels of cell-associated SIV DNA in blood CD4+ T cells and found 
lower levels in Q-VD-OPH–treated SIV-infected RMs as com-
pared with control animals at all time points after treatment (Fig-
ure 8C). Importantly, and consistent with the presence of lower 
levels of virus replication, none of the Q-VD-OPH–treated SIV- 
infected RMs presented clinical signs of AIDS (Figure 8D), 
whereas 8 of 12 animals in the control group developed a wasting 
syndrome — including repetitive diarrhea, weight loss (greater 
than 10%), and anorexia — associated with a decline in CD4+ T 
cell counts, resulting in the euthanasia of RMs in less than 1 year 
after the initial infection.
Figure 7. Expression of cytolytic molecules 
in CD4+ T cells of SIV-infected RMs. (A) Flow 
cytometric analyses of perforin, granzyme B, 
and granulysin expressions in CD4+ T cells from 
peripheral blood of 1 representative healthy 
RM (naive) and 1 SIV-infected RM treated with 
Q-VD-OPH (SIV+Q-VD). (B) Histogram shows the 
percentage of CD4+ T cells expressing perforin, 
granzyme B, and granulysin at day 120 (each dot 
plot represents 1 individual). (C) Percentages and 
(D) cell numbers of CD4+ T cells expressing TIA1 
in either untreated (placebo, n = 6) or Q-VD-OPH–
treated RMs (n = 6) on days 0, 7, 14, 21, 30, 60, 
120, 180, and 360 after infection. Statistical  
differences were assessed using the Mann- 
Whitney U test (*0.01 < P < 0.05; **0.001 < P  
< 0.01; ***P < 0.001). In B–D, values above data 
represent P values. Prism was used to present 
the results in box-and-whisker plots showing the 
minimum and maximum of all the data.
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cell types reported to be abnormally primed to undergo death during 
HIV/SIV infection (61, 96–99), due to the relatively limited availabil-
ity of samples and tissues; however, our observation that the pool of 
CD4+ T cells expressing β7hi (64) is preserved during the acute phase 
and associated with lower levels of sCD14 in Q-VD-OPH–treated 
SIV-infected RMs suggests that this treatment was associated with 
a preserved intestinal CD4+ T cell pool and integrity of the epithe-
lial barrier of the gastrointestinal tract (65–67). Interestingly, at the 
time of necropsy, the ratio of CD4 to CD8 in peripheral LNs as well 
as the spleen and mesenteric LNs was higher in Q-VD-OPH–treated 
SIV-infected RMs as compared with placebo-treated controls, thus 
indicating a global preservation of T cell homeostasis. In this study, 
we have shown for the first time to our knowledge that a strong, 
selective blockade of caspase activation may have a significant bene-
ficial impact on the immunological, virological, and clinical course of 
SIV infection. Importantly, although Q-VD-OPH was injected only 
during the acute phase of infection, the beneficial effect persisted 
throughout the chronic phase. Interesting work published by Whit-
ney et al. (100) demonstrates that blocking viral replication during 
the acute phase with antiretroviral treatment (ART) is not sufficient 
to provide protection once ART is interrupted. Thus, we speculate 
that a dual strategy combining ART with Q-VD-OPH would contrib-
ute to controlling viral rebound. In this sense, it has been shown that 
a vaccination based on the use of Ad26/MVA with TLR improves 
virologic control and delays viral rebound following discontinuation 
The main results of this study are that early and transient 
Q-VD-OPH therapy (a) prevents the activation of caspases and the 
occurrence of T cell death; (b) favors the preservation of both Tcm 
and Tem cells, which is associated with stronger SIV-specific CD4+ 
T cell responses; (c) reduces CD4+ T cell depletion in the gut and 
immune activation; (d) reduces the levels of virus replication; and 
(e) delays the development of AIDS.
Recent studies suggest that early treatment initiation during 
primary HIV-1 infection may reduce viral replication (90), limit viral 
reservoirs (91), and preserve the antiviral host immune response (92, 
93). Recently, the administration of a recombinant rhesus anti-α4β7 
mAb, which maintains normal CD4+ T cell counts in the blood and in 
gut-associated lymphoid tissue (GALT) was found to control viremia 
without the need for further therapy (94). However, the mechanisms 
associated with this long-term protection remain poorly understood. 
Our results demonstrated that treatment with Q-VD-OPH during 
the acute phase of SIV infection is associated with a persistent expan-
sion of specific memory CD4+ T cells. Because at the same time we 
observed lower viremia, we cannot exclude that this process partic-
ipates in the reconstitution of these immune cells, whether these 
immune cells contribute to virologic control, or even both. Of note, 
our observation is consistent with the fact that depletion of CD4+ 
T cells prior to SIV infection of RMs is associated with loss of virus 
control, rapid disease progression, and neurodegenerative diseases 
(95). We have not analyzed in detail all lymphoid or non-lymphoid 
Figure 8. Viral dynamics during primary SIV infection. (A) 
Kinetic analysis of viremia in nontreated RMs (Placebo; n = 
12) and Q-VD-OPH–treated RMs (n = 6). (B) Comparison of 
nontreated (placebo) and Q-VD-OPH–treated RMs. AUCs 
were significantly different (P = 0.01). (C) Frequency of 
SIV-DNA+ CD4+ T cells in blood of SIV-infected RMs treated 
without (placebo, n = 10, filled boxes) or with Q-VD-OPH (n 
= 6, white boxes). (D) Frequency of SIV-DNA+ CD4+ T cells in 
lymphoid tissues (axillary and inguinal LNs, and spleen at 
the day of sacrifice) of SIV-infected RMs treated without 
(placebo, n = 6, filled boxes) or with Q-VD-OPH (n = 6, 
white boxes). (E) Percentage of RMs remaining alive after 
infection without developing an AIDS wasting syndrome 
(AIDS-free). Statistical analysis was assessed using the 
Mann-Whitney U test. Prism was used to present the 
results in box-and-whisker plots showing the minimum and 
maximum of all the data.
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Therefore, we propose that a key immunological effect of Q-VD-
OPH is the relative preservation of CD4+ memory T cell homeo-
stasis, with increased activity of SIV-specific effector CD4+ T cells.
In conclusion, the current study provides evidence that the 
administration of the anti-caspase agent Q-VD-OPH, in the absence 
of ART, during the acute phase of SIV infection in RMs is associated 
with a number of beneficial effects that positively influence the 
immunological, virological, and clinical course of the infection. We 
believe that this molecule may represent a novel adjunctive immu-
notherapeutic approach in the context of HIV infection.
Methods
Animals and virus infection. Eighteen female RMs (Macaca mulatta) of 
Chinese origin, aged 4–5 years, were confirmed prior to infection as 
seronegative for simian T leukemia virus type 1, simian retrovirus type 
1 (type D retrovirus), herpes B viruses, and SIVmac. All animals were 
housed in compliance with French regulations for animal care and use 
and were inoculated intravenously with the pathogenic SIVmac251 
strain (ten 50% animal infectious doses). The pathogenic SIVmac251 
isolate was provided by A.M. Aubertin (INSERM U74, Strasbourg, 
France) and was titrated in Chinese RMs by intravenous inoculation. 
RMs of Chinese origin are useful for monitoring immune dynamics, 
as their pathology closely mimics that in humans (17). Animals (n = 6) 
were treated with Q-VD-OPH (SM Biochemicals; the compound was 
diluted in sterile physiological water in the presence of 15% DMSO) at 
a dose of 20 mg/kg by the intravenous route (1 bolus was injected via 
the saphenous vein) on days 5, 7, 9, 11, and 14 after infection. Untreated, 
control animals were included, one group receiving the placebo (ster-
ile water/DMSO) (n = 6) and a second group receiving sterile water 
only (n = 6). Because no difference was observed between the 2 
control groups, animals were pooled. In our cohort of Chinese RMs, 
we assessed TRIM5a polymorphism. Seventeen of them displayed 
TRIM5aTFP/TFP, while only 1 RM was TRIM5aTFP/Q. Thus, Q/Q was 
extremely rare, consistent with previous report (114). Q-VD-OPH is a 
pan-caspase inhibitor (115, 116), previously reported to block caspase 
activity in neuronal and ischemia pathologies (55, 117). All surgery 
was performed under sodium pentobarbital anesthesia, and all efforts 
were made to minimize suffering. The animals were euthanized for 
ethical reasons when they showed weight loss greater than 10%, 
repetitive diarrhea, and declining CD4+ T cell counts.
Pharmacokinetics of Q-VD-OPH in RMs. A pharmacokinetic anal-
ysis in naive animals using 2 doses of Q-VD-OPH (20 and 40 mg/kg) 
was performed. Q-VD-OPH was quantified in the serum samples at 0, 
0.25, 0.5, 1, 2, 4, 8, and 24 hours and in LNs at 4 hours after intravenous 
injection. Protein precipitation with acetonitrile was used for sera. 
LNs were homogenized using a Precellys tissue homogenizer (Bertin 
Technologies) with a 1:2 v/v water/acetonitrile mixture. Q-VD-OPH 
was quantified using a Waters ACQUITY ultra-performance liquid 
chromatography (UPLC) system with a 2.1 × 50–mm, 1.7-m ACQUITY 
UPLC BEH RP18 shield column coupled to a Waters Qua9ro Premier 
TQ mass spectrometer operated in positive ion electrospray and mul-
tiple reaction monitoring (MRM) mode.
Determination of viral load and quantitative assessment of DNA- 
infected cells. RNA was extracted from the serum of SIV-infected RMs by 
using a Tri Reagent BD kit (Molecular Research Center Inc.). Real-time 
quantitative reverse transcriptase–PCR was used to determine serum 
viral loads. The frequency of SIV-infected cells was determined as previ-
of ART in SIV-infected RMs (101). Therefore, a dual strategy aiming 
to target both the virus and the host immune system leading to the 
induction of robust HIV-specific immune responses may lead to bet-
ter control and an HIV cure.
In this study, we found that the control of viral replication 
mediated by Q-VD-OPH is not dependent on the presence of 
increased numbers of Tem and activated CD8+ T cells. Our results 
indicated that treatment with Q-VD-OPH was associated with 
lower levels of CD8+ T cell activation, which represent a known 
predictive marker of disease progression in RMs of Chinese ori-
gin (13, 16, 17, 75, 102–104). This lower level of immune activa-
tion is consistent with lower viral load and cell-associated SIV 
DNA. However, CD8+ T cells remain sensitive to death during the 
chronic phase of infection, dissociating CD4+ and CD8+ T cell 
responses. We and others have shown that non-pathogenic mod-
els of lentiviral infections displayed some CD8+ (7, 8, 105), but not 
CD4+, T cell apoptosis, indicating different processes.
Our results show that Q-VD-OPH treatment during the acute 
phase of SIV infection is associated with higher levels of CD4+ T 
cells expressing cytotoxic molecules including perforin, granzyme 
B, and granulysin than CD4+ T cells of untreated SIV-infected or 
even healthy, uninfected RMs. It was previously reported that 
SIV-specific CD4+ T cells in SIVΔnef-vaccinated animals express 
perforin and possess direct cytolytic activity (106). It has been also 
reported that cytotoxic CD4+ T cells are associated with early viral 
load set point (107). Furthermore, individuals who controlled viral 
replication had a significant expansion of HIV-specific CD4+ T 
cells compared with individuals who progressed to higher viral set 
points (89). Together, these studies support a role for CD4+ cyto-
toxic T lymphocytes (CTLs) in controlling early viral replication 
and contributing to delayed disease progression. The limitations 
of current highly active ART include the incidence of drug resis-
tance observed in patients, issues of drug adherence, and newly 
acquired infections. Drug resistance represents a key aspect of 
treatment failure (108). Therefore, a possible beneficial effect of 
reinforcing the immune response and controlling the infection 
should be countering the emergence of resistance through the 
generation and recruitment of effector CD4+ T cells.
We and others have previously demonstrated that in HIV- 
infected individuals, caspases are activated through FasL, thus 
leading to apoptosis (9, 10, 21), and that the activation of caspase 
occurs in bystander CD4+ T cells (21, 23, 52). In particular, 
caspase-1 activation is associated with increased inflammation in 
myeloid cells (109–112). Thus, in monocytes/macrophages, which 
are the major source of IL-18, inflammasome activation and secre-
tion of mature IL-18 require the activation of caspase-1 (56, 57). In 
this context, our finding of decreased amounts of IL-18 in Q-VD-
OPH–treated RMs indicated that this compound targets caspase-1 
in vivo, consistent with the in vitro data (Supplemental Figure 
1B), and that Q-VD-OPH modulates inflammasome activity in 
monocytes/macrophages. As such, Q-VD-OPH appears to act as a 
potent in vivo modulator of pyroptosis (21, 23, 52). The decrease in 
IL-18 and FasL associated with Q-VD-OPH treatment during the 
acute phase of SIV infection may also have an indirect impact on 
the levels of CD4+ T cell apoptosis, as anti-FasL treatment during 
the initial stages of SIV infection has been reported to preserve T 
cell homeostasis and sustain cell-mediated immunity to SIV (113). 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 6 3 7jci.org   Volume 128   Number 4   April 2018
stained with anti-CD4 and anti-CD3 mAbs (BD Biosciences), then 
washed twice in PBS, and further incubated with TNF-α and anti–IFN-γ 
(clone 4S.B3; BD Biosciences) after membrane permeabilization. Cells 
were examined for expression of perforin, granzyme B, granulysin, 
and TIA1 after cell surface staining and then fixed/permeabilized with 
a Cytofix/Cytoperm Kit (BD Biosciences), according to manufactur-
er’s instructions, and stained intracellularly for perforin (clone Pf344, 
Mabtech), granzyme B (clone GRB04, Invitrogen), granulysin (ebio-
DH2, eBioscience), and TIA1 (clone PNIM3293, Beckman Coulter) 
(75). Samples were acquired on a Cytomics FC 500 flow cytometer and 
analyzed using FlowJo software (version 10.06).
Quantitation of FasL, IL-18, and sCD14 in sera of SIV-infected mon-
keys. FasL in serum was measured using ELISA (MBL). The assay 
uses anti-FasL mAbs (clones 4H9 and 4A5). The peroxidase substrate 
was used to quantify FasL and the optical density measured at 450 
nm. Concentration was determined using a standard curve based on 
recombinant FasL (61). IL-18 was measured by using an ELISA kit 
(MBL Biomedical, CliniSciences). The concentration was determined 
using a standard curve based on recombinant IL-18 (58). Commercial 
ELISA was used to measure sCD14 (R&D Systems).
Reagents. Reagents used in the study included AEBSF, aprotinin, 
elastinal, and TLCK (Tosyl-l-lysyl-chloromethane hydrochloride), 
which inhibit serine proteases, purchased from Sigma-Aldrich; E64 
and leupeptin, which inhibit cysteine proteases, purchased from Sigma- 
Aldrich; pepstatin A, which inhibits aspartyl proteases, purchased from 
Sigma-Aldrich; 1,10-phenanthroline, an inhibitor of metallopeptidases, 
purchased from Sigma-Aldrich; N-acetyl-Leu-Leu-norleucinal (ALLN), 
calpeptin, calpastatin, and Z-FA-CHO, which inhibit calpain proteases, 
purchased from Calbiochem; Z-Phe-Gly-NHO-Bz, an inhibitor of cyste-
ine cathepsins, purchased from Calbiochem; and  Q-VD-OPH, a broad 
caspase inhibitor, purchased from Calbiochem.
Statistics. Data are reported as mean ± SEM, and groups were 
compared using Mann-Whitney U test or paired Student’s t test with 
Prism version 6.0 (GraphPad Software). AUC was also calculated; a P 
value less than 0.05 was considered significant.
Study approval. All animal experiments described in the present 
study were conducted at the Institute Pasteur according to the Euro-
pean Union guidelines for the handling of laboratory animals (http://
ec.europa.eu/environment/chemicals/lab_animals/home_en.htm). 
The numbers of animals treated with the compound were defined 
according to the European guidelines for nonhuman primates and the 
3Rs principles (Replacement, Reduction and Refinement). The proto-
col was approved by the Committee on the Ethics of Animal Experi-
ments of Île de France (PARIS 1, #20080007).
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